SLDB Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

SPRZEDAż 107693 min ago

@ $8.00

Wydano: 14 vas. 2024 @ 16:30

Zwrot: 12.25%

Poprzedni sygnał: vas. 13 - 16:30

Poprzedni sygnał: Kupno

Zwrot: 4.30 %

Live Chart Being Loaded With Signals

Commentary (26 bal. 2024 @ 23:00):

Stats
Dzisiejszy wolumen	188 735
Średni wolumen	266 730
Kapitalizacja rynkowa	339.06M
EPS	$0 ( 2024-03-28 )
Następna data zysków	( $-0.570 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.860
ATR14	$0.0310 (0.35%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-03	Smith Ian F	Buy	3 256	Common Stock
2024-04-03	Smith Ian F	Sell	3 256	Restricted Stock Units
2024-02-13	Hanrahan Jessie	Buy	65 000	Employee Stock Option (Right to Buy)
2024-02-13	Hanrahan Jessie	Buy	32 500	Restricted Stock Units
2024-02-13	Cumbo Alexander	Buy	240 250	Employee Stock Option (Right to Buy)

INSIDER POWER
95.48
Last 96 transactions
Buy: 8 088 873 \| Sell: 207 617

Wolumen Korelacja

Długi: 0.17 (neutral)

Krótki: 0.82 (strong)

Signal:(65.816) Same movement expected

Solid Biosciences Inc Korelacja

10 Najbardziej pozytywne korelacje
CIZN	0.814

10 Najbardziej negatywne korelacje
CATB	-0.823

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Solid Biosciences Inc Korelacja - Waluta/Towar

0.02
( neutral )

-0.26
( neutral )

0.00
( neutral )

0.42
( neutral )

0.79
( moderate )

0.60
( weak )

Solid Biosciences Inc Finanse

Annual	2023
Przychody:	$0
Zysk brutto:	$-2.58M (0.00 %)
EPS:	$-4.83

FY	2023
Przychody:	$0
Zysk brutto:	$-2.58M (0.00 %)
EPS:	$-4.83

FY	2022
Przychody:	$8.09M
Zysk brutto:	$5.69M (70.25 %)
EPS:	$-7.70

FY	2021
Przychody:	$13.62M
Zysk brutto:	$0.00 (0.00 %)
EPS:	$-10.14

Financial Reports:

No articles found.

Solid Biosciences Inc

Solid Biosciences Inc. engages in developing therapies for duchenne muscular dystrophy in the United States. The company's lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to drive functional dystrophin protein expression in patients' muscles; and SGT-003, a ext-generation gene transfer candidate for the treatment of duchenne muscular dystrophy. It also engages in developing of platform technologies, including dual gene expression, a technology for packaging multiple transgenes into one vector, as well as novel capsids. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne Muscular Dystrophy. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.